Collegium Pharmaceutical (354) Ownership - Who Owns Collegium Pharmaceutical?
Collegium Pharmaceutical (354) Ownership Overview
- 3.30% Insiders
- 32.29% Mutual Funds
- 1.38% Other Institutional Investors
- 33.31% ETFs
- 29.73% Public Companies and Individual Investors
The ownership structure of Collegium Pharmaceutical (DE:354) stock is a mix of institutional, retail, and individual investors. Approximately 66.98% of the company’s stock is owned by Institutional Investors, 3.30% is owned by Insiders, and 29.73% is owned by Public Companies and Individual Investors.
The ownership structure of Collegium Pharmaceutical (DE:354) stock is a mix of institutional, retail, and individual investors. Approximately 66.98% of the company’s stock is owned by Institutional Investors, 3.30% is owned by Insiders, and 29.73% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| May 19, 2026 | John Gordon Freund | $681 | |
| May 17, 2026 | John Gordon Freund | $142,547 | |
| May 14, 2026 | Nancy Lurker | $161,820 | |
| May 12, 2026 | Garen Bohlin | $323,466 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Graham Capital Management, L.p. | €323,637 | |
| Dec 31, 2025 | Royce & Associates Llc | €11,628,383 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Ishares | 3,798,409 | Institution | 11.67% | 89,380,362 |
| Vanguard | 1,832,884 | Institution | 5.63% | 43,129,593 |
| Capitol Series Trust | 1,561,408 | Institution | 4.80% | 36,741,492 |
| Vanguard Index Funds | 1,347,828 | Institution | 4.14% | 31,715,741 |
| Mutual Fund Series Trust | 1,344,376 | Institution | 4.13% | 31,634,512 |
| Invesco | 1,235,173 | Institution | 3.79% | 29,064,856 |
| Spdr | 1,002,757 | Institution | 3.08% | 23,595,875 |
| Steven A. Tananbaum | 744,889 | Institution | 2.29% | 17,527,983 |
| Principal Funds, Inc | 668,068 | Institution | 2.05% | 15,720,308 |
| Dfa | 621,075 | Institution | 1.91% | 14,614,516 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Capitol Series Trust | 1,561,408 | Institution | 4.80% | 36,741,492 |
| Vanguard Index Funds | 1,347,828 | Institution | 4.14% | 31,715,741 |
| Mutual Fund Series Trust | 1,344,376 | Institution | 4.13% | 31,634,512 |
| Principal Funds, Inc | 668,068 | Institution | 2.05% | 15,720,308 |
| Mfs Series Trust I | 585,155 | Institution | 1.80% | 13,769,282 |
| Fidelity Salem Street Trust | 395,187 | Institution | 1.21% | 9,299,145 |
| Dfa Investment Dimensions Group Inc | 393,574 | Institution | 1.21% | 9,261,190 |
| Mfs Series Trust Xiii | 354,483 | Institution | 1.09% | 8,341,339 |
| Fidelity Concord Street Trust | 325,730 | Institution | 1.00% | 7,664,753 |
| Royce Fund | 293,127 | Institution | 0.90% | 6,897,571 |
FAQ
Who Owns Collegium Pharmaceutical (DE:354)?
According to the latest TipRanks data, approximately 66.98% of the company's stock is held by institutional investors, 3.30% is held by insiders, and 29.73% is held by public companies and individual investors.
What percentage of Collegium Pharmaceutical (DE:354) stock is held by institutional investors?
According to the latest TipRanks data, approximately 66.98% of Collegium Pharmaceutical (DE:354) stock is held by institutional investors: 32.29% by mutual funds, 33.31% by ETFs and 1.38% by other institutional investors.
What percentage of Collegium Pharmaceutical (DE:354) stock is held by retail investors?
According to the latest TipRanks data, approximately 29.73% of Collegium Pharmaceutical (DE:354) stock is held by public companies and individual investors.
Who owns the most shares of Collegium Pharmaceutical (DE:354)?
iShares owns the most shares of Collegium Pharmaceutical (DE:354).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.